Ubs Group Ag Gain Therapeutics, Inc. Call Options Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GANX
# of Institutions
37Shares Held
3.52MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$988,5280.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$951,0980.05% of portfolio
-
Jones Financial Companies Lllp428KShares$718,5360.0% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$474,1140.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$428,3830.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $20M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...